Madhu Mazumdar, Ph.D., M.A., M.S.

Professor of Biostatistics in Public Health
Chief, Division of Biostatistics and Epidemiology
Weill Cornell Medical College

Selected Recent Publications:

Lavoie P, Rutledge J, Dawoud MA, Mazumdar M, Riina H, Gobin YP. Predictors and Timing of Hypotension and Bradycardia after Carotid Artery Stenting American Journal of Neuroradiology August 21, 2008.

Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007 Jan 20;25(3):247-56

Bang H , Vupputuri S, Shoham DA, Klemmer PJ, Falk, RJ, Mazumdar M, Gipson D, Colindres RE, and Kshirsagar AV.: SCreening for Occult REnal Disease (SCORED): A Simple Prediction Model for Chronic Kidney Disease. Archives of Internal Medicine 2007 Feb 26;167(4):374-81.

Bang H, Mazumdar M, Spence JD.: Tutorial in Biostatistics: Analyzing Associations between Total Plasma Homocysteine and B vitamins using Optimal Categorization and Segmented Regression. Neuro Epidemiology 2006;27(4):188-200.

Mazumdar M, Zhou KX, Tu D. (2006) Some design issues underlying strata-matched non-randomized comparative studies with survival outcome. Stat in Med 25, 3949-3959

Mazumdar M, Smith A, Debroy PP, Schwartz LH. (2005) A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. J Clin Epidemiol 58(2):150-3.

Liu A, Schisterman EF, Mazumdar M, Hu J. (2005) Power and Sample Size Calculation of Comparative Diagnostic Accuracy Studies with Multiple Correlated Test Results. Biometrical J 47(2), 140-150

Mazumdar M, Smith A, Schwartz LH. (2004) A Statistical Simulation Finds Discordance in Response Assessment by World Health Organization (WHO) Criterion And Response Evaluation Criteria In Solid Tumors (RECIST) Guideline. J Clin Epidemiol 57(4):358-65.

Pignon JP, Syz N, Posner M, Olivares R, Laurence LL, Antoine Y, Dunant A, Lewin F, Dalley DN, Paccagnella A, Taylor SG, Domenge C, Bourhis J, Mazumdar M. (2004) Adjusting for Patient Selection Suggests the Addition of Docetaxel to 5–Fluorouracil–Cisplatin Induction Therapy May Offer Survival Benefit in Squamous Cell Cancer of the Head and Neck. Anti-Cancer Drugs 15(4): 331-40.

Bacik J, Mazumdar M, Murphy BA, Fairclough DA, Eremenco S, Mariani T, Motzer RJ, and Cella D. (2004) The Functional Assessment of Cancer Therapy-BRM (FACT-BRM): A New Tool for the Assessment of Quality of Life in Patients Treated with Biologic Response Modifiers. Quality Life Res 13(1): 137-54.

Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M.: (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22(3), 454-63.

Mazumdar M. (2004) Group sequential design for comparative diagnostic accuracy studies: Implications and guidelines for practitioners. Medical Decision Making 24(5):525-533.

Motzer RJ. Bacik J. Mazumdar M. (2004) Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 10(18):630, 2S-3S.

Mazumdar M, Liu A. (2003) Group Sequential Design for comparative diagnostic accuracy studies. Stat in Med 2:727-739.

Mazumdar M, Bacik J, Tickoo SK, Dobrzynski D, Donadio A, Bajorin DF, Motzer RJ, Reuter VE, Bosl GJ. (2003) Cluster analysis of p53 and ki67 expression, apoptosis, alpha-fetoprotein and human chorionic gonadotrophin discovers a good prognostic subgroup within embryonal carcinoma germ cell tumor. J Clin Oncol 21(14): 2679-88.

Mazumdar M, Smith A, Bacik J. (2003) Methods for categorizing a prognostic variable in a multivariable setting. Stat in Med 22(4):559-571.

Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. (2003) Postoperative nomogram for disease specific survival after an RO resection for gastric carcinoma. J Clin Oncol 21, 3647-3650.

Mazumdar M. (2002) The impact of covariate imbalance on the size of the logrank test in randomized clinical trials by Kinukawa N, Nakamura T, Akazawa K, Nose Y (Stat Med 2000;19:1955-1967) (Letter) Stat in Med 21(8):1167-71.

Mazumdar M, Fazzari M, Panageas KS. (2001) A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat in Med 20:883-892.

Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. (2001) Predicting outcome of chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19:2534-2541.

Mazumdar M, Smith A, Tong WP, Motzer RJ. (2000) Calvert’s formula for dosing carboplatin: Overview and concerns of applicability in high-dose setting. J Natl Cancer Inst 92:1434-1436.

Mazumdar M, Glassman JR.: (2000) Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat in Med 19:113-132.

Madhu Mazumdar, Ph.D., M.A., M.S. Madhu Mazumdar, Ph.D., M.A., M.S.
Top of page